Navigation Links
Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
Date:8/7/2008

SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, 2008 at 11:30 a.m. (Eastern Time) at the Four Seasons Hotel in Boston, MA.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts:

Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

amerriweather@monogrambio.com

Jeremiah Hall

Feinstein Kean Healthcare

Tel: 415 677-2700

jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
2. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
3. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
4. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
5. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
6. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
7. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
8. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
9. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
10. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
11. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Foresight Institute, a leading think tank, ... announced the winners for the 2017 Foresight Institute Feynman Prizes.These are given in ... , Established in 1993 and named in honor of pioneer physicist Richard Feynman, ...
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling ... early-stage tech companies. “Grit” author Angela Duckworth and her team at Character Lab ... is Cooley, an international law firm with decades of experience supporting high-growth companies ...
(Date:9/19/2017)... FRANCISCO , Sept. 19, 2017 ValGenesis ... Solutions (VLMS) is pleased to announce the strategic partnership ... to provide clients with validation services using the latest ... partner, VTI will provide clients with efficient and cost-effective ... a marketing partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, ... applications, announced today that two new patents have been allowed by the USPTO ... of Band-LOK, said, “We continue to explore additional clinically-relevant designs for both the ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):